Background #
Heart failure is a clinical syndrome characterized by the heart’s inability to pump sufficient blood to meet the metabolic demands of the body. It results from structural or functional cardiac disorders impairing ventricular filling or ejection of blood.
Classification/Types
Heart failure is classified based on several factors:
Based on Ejection Fraction:
| Type | EF (%) | Pathophysiology | Common Causes |
|---|---|---|---|
| HFrEF (Heart Failure with reduced EF) | ≤40% | Systolic dysfunction: impaired contraction of LV | CAD, MI, dilated cardiomyopathy |
| HFmrEF (Heart Failure with mildly reduced EF) | 41–49% | Intermediate phenotype; partly systolic and partly diastolic | Mixed causes |
| HFpEF (Heart Failure with preserved EF) | ≥50% | Diastolic dysfunction: impaired relaxation and filling | HTN, aging, obesity, diabetes, HCM |
| HFimpEF (Heart Failure with improved EF) | Previous EF ≤40%, now >40% | Previous systolic dysfunction with subsequent improvement | Variable, often with optimal medical therapy |
Note: HFrEF is also known as Systolic Dysfunction. HFpEF is similarly referred to as Diastolic Dysfunction. The HFimpEF category was introduced in the 2022 ACC/AHA/HFSA guidelines to describe patients with previous HFrEF who have shown improvement in ejection fraction.[1]
Causes of HFrEF (EF ≤40%)
Primary mechanism: Impaired contractility/systolic dysfunction.
???? Ischemic causes (most common)
- Myocardial infarction (MI)
- Chronic coronary artery disease (CAD)
- Hibernating myocardium
???? Non-ischemic cardiomyopathies
- Dilated cardiomyopathy (idiopathic, familial/genetic)
- Toxic: Alcohol, cocaine, chemotherapy (e.g., doxorubicin, trastuzumab)
- Infectious: Viral myocarditis (e.g., Coxsackievirus, adenovirus)
- Peripartum cardiomyopathy
- Tachycardia-induced cardiomyopathy (e.g., from AF with RVR)
???? Pressure/volume overload
- Chronic hypertension
- Aortic or mitral regurgitation
- Severe aortic stenosis (late stages)
???? Metabolic and systemic
- Thyroid dysfunction (especially hyperthyroidism)
- Nutritional (thiamine deficiency — wet beriberi)
- Iron overload (hemochromatosis)
???? Infiltrative/autoimmune
- Sarcoidosis
- Systemic lupus erythematosus (rare)
Causes of HFpEF (EF ≥50%)
Primary mechanism: Impaired relaxation/diastolic dysfunction + ventricular stiffness.
???? Common comorbid conditions
- Chronic hypertension (leads to LV hypertrophy)
- Aging (decreased compliance)
- Obesity (increased cardiac workload)
- Diabetes mellitus
- Coronary artery disease (ischemia without infarction)
???? Cardiomyopathies
- Hypertrophic cardiomyopathy
- Restrictive cardiomyopathy:
- Amyloidosis
- Hemochromatosis (early stage)
- Sarcoidosis
???? Valvular disease
- Aortic stenosis (early stages)
- Mitral stenosis
???? Other
- Atrial fibrillation (impairs LV filling)
- High-output states (e.g., anemia, thyrotoxicosis — in vulnerable patients)
- Constrictive pericarditis
Based on Anatomy: Left-Sided vs Right-Sided Heart Failure
Left-Sided Heart Failure (LHF)
???? Inability of the left ventricle to pump blood effectively to the systemic circulation.
Causes:
- Ischemic heart disease (MI, CAD)
- Hypertension
- Aortic stenosis
- Mitral regurgitation
- Dilated or hypertrophic cardiomyopathy
Key Clinical Features:
- Pulmonary congestion (due to backup into lungs)
- Dyspnea on exertion
- Orthopnea
- Paroxysmal nocturnal dyspnea (PND)
- Bibasilar crackles/rales
- Pulmonary edema (pink frothy sputum)
- Dyspnea
- Cool extremities (low perfusion)
Right-Sided Heart Failure (RHF)
???? Inability of the right ventricle to pump blood effectively into the pulmonary circulation.
Causes:
- Left-sided heart failure (most common)
- Pulmonary hypertension
- COPD → cor pulmonale
- Pulmonary embolism
- Tricuspid or pulmonary valve disease
- Right ventricular infarct (RMI)
Key Clinical Features:
- Systemic venous congestion:
- Jugular venous distention (JVD)
- Hepatomegaly, Hepatojugular reflux
- Ascites
- Peripheral edema (legs, sacrum)
- Weight gain
Congestive Heart Failure (CHF)
CHF is a term used when both sides are failing. It often starts as LHF → leads to RHF due to pulmonary pressure overload. Presents with combined pulmonary and systemic congestion.
| Feature | Left HF | Right HF |
|---|---|---|
| Main cause | CAD, HTN | LHF, pulmonary disease |
| Backup | Into lungs | Into systemic veins |
| Symptoms | Dyspnea, orthopnea, fatigue | JVD, edema, ascites |
| Key signs | Rales, S3, PND | Hepatomegaly, peripheral edema |
Based on Timing of Onset:
Acute vs. Chronic: Acute HF presents suddenly, while chronic HF develops over time with periods of stability and exacerbation.
Acute Decompensated Heart Failure (ADHF)
Acute Decompensated Heart Failure is a sudden or gradual worsening of heart failure symptoms, usually in a patient with pre-existing chronic HF. It is a medical emergency and a leading cause of hospitalization in older adults.
ADHF = acute worsening of cardiac function → volume overload, poor perfusion, or both
May present as:
- Worsening of chronic HF (most common)
- New-onset (“de novo”) heart failure (e.g., from MI or hypertensive crisis)
Triggers/Precipitating Causes (“FAILURES”):
| Mnemonic | Description |
|---|---|
| F – Forgot medications | Noncompliance with diuretics or HF meds |
| A – Arrhythmias | Atrial fibrillation, VT, bradyarrhythmias |
| I – Ischemia | Acute MI, unstable angina |
| L – Lifestyle | High salt/fluid intake, alcohol |
| U – Upregulation of CO | Infection, anemia, fever, thyrotoxicosis |
| R – Renal failure | Volume retention, worsening uremia |
| E – Embolism | PE causing acute RV strain |
| S – Stenosis/Structural | Valve disease (e.g., aortic stenosis), cardiomyopathies |
High-Output Heart Failure
High-output heart failure is a less common form of heart failure where cardiac output is elevated, but still inadequate to meet the body’s metabolic demands. Unlike typical low-output heart failure, the problem isn’t weak pumping — it’s the body’s excessive demand or abnormally low systemic vascular resistance.
High-output heart failure occurs when the heart is pumping more than normal (>8 L/min), yet the tissues remain hypoperfused due to:
- Low systemic vascular resistance, or
- Increased metabolic demand
The heart itself may be structurally normal or even hyperdynamic initially, but sustained overwork leads to eventual cardiac dysfunction.
Common Causes (Mnemonic: AV FISTULA)
| Cause | Mechanism |
|---|---|
| Anemia | ↓ Oxygen-carrying capacity → ↑ cardiac demand |
| Vitamin B1 deficiency (wet beriberi) | Vasodilation, impaired myocardial metabolism |
| Fistulas (arteriovenous) | Bypass capillaries → ↓ resistance → ↑ preload |
| Infection (sepsis) | Cytokine-induced vasodilation |
| Systemic vasodilation (e.g., cirrhosis) | ↓ SVR → ↑ cardiac output to maintain pressure |
| Thyrotoxicosis | ↑ metabolic rate and sympathetic activity |
| Uremia | Toxins → vasodilation, anemia |
| Liver disease (esp. cirrhosis, hepatorenal syndrome) | Splanchnic vasodilation |
| Alcoholic wet beriberi | Thiamine deficiency-induced heart failure |
Epidemiology
Heart failure affects approximately 6.7 million Americans over age 20, with prevalence projected to rise to 8.7 million by 2030 and 11.4 million by 2050.[2] The lifetime risk is 24% (approximately 1 in 4 persons).[2] Globally, HF affects an estimated 64 million people.[3,4] While HF incidence has stabilized in high-income countries, prevalence continues to increase due to aging populations and improved survival.[3,4] HF-related mortality has accelerated, with 425,147 deaths in 2020-2021 (45% of cardiovascular deaths).[2] Significant racial disparities persist, with Black, American Indian, and Alaska Native individuals having the highest mortality rates.[2]
Pathophysiology
Heart failure develops when cardiac output falls as a result of cardiac injury. The primary compensatory mechanisms include activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS), collectively termed “neurohormonal activation.”[5,6]
In the short term, neurohormonal activation maintains cardiovascular homeostasis through several coordinated responses. SNS activation increases heart rate, myocardial contractility, and peripheral vasoconstriction via catecholamines. Simultaneously, RAAS activation causes vasoconstriction through angiotensin II and increases blood volume through salt and water retention mediated by aldosterone. Vasopressin is released to further promote water retention, while natriuretic peptides provide a counter-regulatory response to excessive vasoconstriction.[5,6]
However, with chronic activation, these initially beneficial compensatory mechanisms become maladaptive and lead to deleterious effects on both the heart and circulation. Progressive cardiac remodeling occurs, characterized by chamber dilation, wall thinning, and increased sphericity. Myocardial fibrosis develops, particularly driven by aldosterone, while cardiac myocytes undergo apoptosis, hypertrophy, and focal necrosis. The sustained sympathetic stimulation results in β-adrenergic receptor downregulation, which reduces myocardial responsiveness to catecholamines. Both afterload and preload increase, and progressive salt and water retention leads to the development of edema.[5,6]
The pattern of ventricular remodeling depends on the type of hemodynamic stress imposed on the heart. When the overload is predominantly pressure-related, such as in hypertension or aortic stenosis, the heart develops concentric hypertrophy through parallel addition of sarcomeres, resulting in myocyte widening. Conversely, when volume overload predominates, as seen in mitral regurgitation, eccentric hypertrophy develops through series addition of sarcomeres, leading to myocyte lengthening and chamber dilation.[5,6]
Neurohormonal activation is now recognized as one of the most important mechanisms underlying HF progression, making therapeutic antagonism of these systems the cornerstone of contemporary HF pharmacotherapy.[5,6]
Etiology #
Primary Causes:
- Ischemic heart disease (most common in HFrEF)
- Hypertension (especially in HFpEF)
- Valvular heart disease
- Cardiomyopathies (dilated, hypertrophic, restrictive)
- Arrhythmias (e.g., atrial fibrillation)
Risk Factors:
- Diabetes mellitus
- Smoking
- Obesity
- Chronic kidney disease
- Sleep apnea
- Advanced age
- Excessive alcohol use
- Family history of cardiomyopathy
Clinical Presentation #
History (Symptoms)
- Exertional dyspnea and/or dyspnea at rest
- Orthopnea
- Acute pulmonary edema (PND, frothy sputum, wheezing)
- Chest pain/pressure and palpitations
- Fatigue and weakness
- Nocturia and oliguria
- Anorexia, weight loss, nausea
Physical Exam (Signs)
General Exam: Patient may appear dyspneic, anxious, or in respiratory distress with use of accessory muscles
Vital Signs:
- Blood Pressure: Hypotension in advanced HF
- Pulse:
- Tachycardia due to sympathetic stimulation
- Weak, rapid, and thready pulse
- Respiratory Rate: Tachypnea from pulmonary edema
- O2 sat: Hypoxia in decompensated states
Cardiovascular:
- S3 gallop: Sign of volume overload and systolic dysfunction
- Displaced apical impulse: Suggests LV hypertrophy or dilation
- Jugular venous distention (JVD): Indicates elevated right-sided pressures
- Pulsus alternans: Alternating strong and weak pulse in advanced HF
Respiratory:
- Bibasilar crackles or rales: Pulmonary edema
- Wheezing (“cardiac asthma”)
- Pleural effusions: Often bilateral, right > left
Abdominal:
- Hepatomegaly and hepatojugular reflux: From hepatic congestion
- Ascites: Seen in severe right-sided HF
- Anasarca: Generalized swelling
Peripheral Vascular:
- Pitting edema in lower extremities
- Cool extremities in low output states
Neurological:
- Confusion, dizziness: Hypoperfusion in advanced cases
Differential Diagnosis #
- COPD/Asthma exacerbation: Wheezing, no orthopnea or edema
- Pneumonia: Fever, consolidation on imaging
- Pulmonary embolism: Pleuritic chest pain, sudden onset dyspnea
- CKD/Nephrotic syndrome: Edema without dyspnea
- Liver cirrhosis: Ascites, but no pulmonary signs
Diagnosis #
Diagnostic Criteria
Framingham Criteria
Requires ≥2 major or 1 major + 2 minor criteria to diagnose heart failure:
Major:
- PND
- Neck vein distension
- Rales
- Cardiomegaly on CXR
- Pulmonary edema
- S3 gallop
- Weight loss ≥4.5 kg with treatment
Minor:
- Peripheral edema
- Night cough
- Dyspnea on exertion
- Hepatomegaly
- Pleural effusion
- Tachycardia
- Nocturnal dyspnea
Initial Testing
Echocardiogram (transthoracic):
- Best initial test to evaluate HF
- Most important tool for evaluating EF, chamber size, wall motion, valvular disease
- Classify HF as HFrEF, HFmrEF, HFpEF, or HFimpEF
12-lead ECG:
- May show arrhythmias, prior MI, LV hypertrophy
BNP or NT-proBNP:
- BNP = B-type natriuretic peptide; NT-proBNP = N-terminal proBNP (BNP precursor)
- Elevated in heart failure; helps distinguish from non-cardiac causes of dyspnea especially in atypical presentation
Conditions with Elevated BNP/NT-proBNP (besides Heart Failure):
- Cardiac: Acute coronary syndrome, myocarditis, pericarditis, atrial fibrillation, pulmonary hypertension, valvular heart disease, hypertrophic cardiomyopathy
- Renal: Chronic kidney disease, acute kidney injury (especially NT-proBNP)
- Pulmonary: Pulmonary embolism, acute respiratory distress syndrome, severe COPD
- Other: Advanced age (>75 years), sepsis, critical illness, stroke, subarachnoid hemorrhage, severe burns
Difference Between BNP and NT-proBNP:
BNP (B-type Natriuretic Peptide):
- Active hormone (biologically active)
- Shorter half-life (~20 minutes)
- Cleared by kidney and natriuretic peptide receptors
- Less affected by renal function
NT-proBNP (N-terminal pro-BNP):
- Inactive fragment (biologically inactive)
- Longer half-life (~120 minutes)
- Cleared primarily by kidneys
- More affected by renal dysfunction (higher levels in CKD)
- More stable for laboratory measurement
- Higher baseline levels, especially with age
Both are equally useful for diagnosing/excluding HF, but cutoffs differ. NT-proBNP tends to be higher numerically and is more affected by age and renal function.
Chest X-ray:
- Typically shows cardiomegaly, pulmonary vascular congestion, Kerley B lines, pleural effusions
Additional Testing
| Test | Findings/Purpose |
|---|---|
| CBC | May show anemia (common contributor to HF symptoms) |
| CMP | Hyponatremia (worsening prognosis), elevated BUN/creatinine, abnormal LFTs in hepatic congestion |
| RFT | BUN and Creatinine |
| LFT | AST, ALT, LDH – Associated congestive hepatomegaly, cardiac cirrhosis |
| Lipid panel | Assess atherosclerotic risk |
| Thyroid panel | Rule out hypo-/hyperthyroidism as reversible causes |
| Cardiac Enzymes (CK-MB, Troponins) | May be elevated in decompensation or coexisting ischemia |
| Iron studies | Screen for iron deficiency (common in HF, treatable) |
Other Imaging
- Cardiac MRI: For infiltrative or inflammatory cardiomyopathies
- Nuclear stress testing or coronary angiography: To assess for ischemic etiology
Treatment #
Acute Decompensated HF (ADHF)
Pharmacologic Management
For Patients with Fluid Overload (Most Common)
Diuretics (First-line):
- IV loop diuretics (furosemide 40-80 mg IV bolus or continuous infusion) [7][8]
- Dose should equal or exceed home oral dose when given IV
- Monitor urine output, daily weights, and electrolytes
- Consider diuretic combinations if refractory (add thiazide or metolazone) [9]
Based on Blood Pressure Profile:
Hypertensive ADHF (SBP >140 mmHg):
- IV vasodilators (nitroglycerin or nitroprusside) for immediate afterload reduction [10]
- Continue loop diuretics for decongestion
Normotensive ADHF (SBP 90-140 mmHg):
- IV loop diuretics as primary therapy [7]
- GDMT (guideline-directed medical therapy) continuation if tolerated
Hypotensive ADHF (SBP <90 mmHg) with Cardiogenic Shock:
- Inotropes (dobutamine or milrinone) for hemodynamic support [11]
- Consider mechanical circulatory support if refractory
- Avoid vasodilators and consider reducing or holding diuretics initially
Non-Pharmacologic Management
Oxygen Therapy:
- Supplemental oxygen for SpO₂ <90%[9]
- Non-invasive ventilation (NIV): CPAP or BiPAP for severe respiratory distress reduces intubation rates and mortality [13][14]
- Mechanical ventilation if respiratory failure despite NIV
Fluid & Sodium Restriction:
- Fluid restriction <2 L/day in severe cases
- Sodium restriction <2-3 g/day[15]
Chronic HF Management (Guideline-Directed Medical Therapy – GDMT)
The 2022 ACC/AHA/HFSA guidelines established a “4-pillar” approach to HFrEF treatment, with therapies that should be initiated rapidly (ideally within 3 months of diagnosis) and uptitrated to target doses.[1,16]
Medications with Mortality Benefit:
For HFrEF (EF ≤40%):
| Medication Class | Examples | Mortality Benefit | Indication | Class/LOE |
|---|---|---|---|---|
| ARNI (Angiotensin Receptor-Neprilysin Inhibitors) | Sacubitril/valsartan (Entresto) | Yes | Preferred over ACEi/ARB for HFrEF; NYHA class II-III | I/B-R |
| ACE inhibitors | Lisinopril, enalapril, captopril | Yes | All HFrEF patients if ARNI not used | I/A |
| ARBs | Losartan, valsartan | Yes | Alternative to ACEi if not tolerated; not used if on ARNI | I/A |
| Beta-blockers | Carvedilol, metoprolol succinate, bisoprolol | Yes | All HFrEF patients unless contraindicated | I/A |
| Mineralocorticoid receptor antagonists (MRAs) – Steroidal | Spironolactone, eplerenone | Yes | EF ≤35%, NYHA II–IV | I/A |
| MRAs – Non-steroidal | Finerenone | Yes | HFmrEF/HFpEF (EF ≥40%) | Emerging |
| SGLT2 inhibitors | Dapagliflozin, empagliflozin | Yes | HFrEF, HFmrEF, or HFpEF; regardless of diabetes status | I/A |
| Hydralazine + isosorbide dinitrate | – | Yes (in Black patients) | NYHA III–IV despite optimal therapy or intolerance to ACEi/ARB/ARNI | I/B |
| Ivabradine | – | No mortality reduction | For HR >70 bpm despite max beta-blocker dose, EF ≤35% | IIa/B-R |
| Diuretics | Furosemide, bumetanide, torsemide | Symptom relief only | For volume overload; monitor electrolytes | I/C |
New Evidence for HFmrEF and HFpEF (EF ≥40%):
The 2024 FINEARTS-HF trial demonstrated that finerenone, a non-steroidal MRA, significantly reduced the composite of cardiovascular death and total worsening HF events in patients with HFmrEF and HFpEF (EF ≥40%).[17,18] Over a median follow-up of 32 months:
- Primary outcome events occurred in 624 patients (finerenone) vs 719 patients (placebo)
- Rate ratio: 0.84 (95% CI 0.74-0.95, p=0.007)
- Total worsening HF events: 842 vs 1,024 (RR 0.82, p=0.006)
- Cardiovascular death: 8.1% vs 8.7% (HR 0.93, not significant)
- Benefit was consistent across the EF spectrum and in patients already on SGLT2 inhibitors [17,18]
This represents the first definitive evidence that an MRA is beneficial in HFmrEF/HFpEF, potentially establishing finerenone as a “second pillar” of therapy alongside SGLT2 inhibitors for these patient populations.[17,18]
Contraindications to Beta-Blockers:
- Acute decompensated HF
- Bradycardia or heart block
- Severe asthma/COPD exacerbation
- Cardiogenic shock
Device Therapy
Implantable Cardioverter Defibrillator (ICD):
Indication: EF ≤35%, NYHA II–III despite optimal medical therapy (Class I)
An ICD is a device implanted in patients at high risk of sudden cardiac death (SCD) due to life-threatening ventricular arrhythmias, particularly in HFrEF.
Function:
- Monitors heart rhythm continuously
- Delivers:
- Pacing for bradycardia or minor arrhythmias
- Anti-tachycardia pacing (ATP) or
- Defibrillation shocks to terminate ventricular tachycardia/fibrillation
Cardiac Resynchronization Therapy (CRT):
Indication: EF ≤35%, wide QRS (≥150 ms), LBBB morphology, NYHA II-IV on optimal GDMT (Class I)
CRT is a specialized pacing therapy used in HFrEF to improve ventricular synchrony, especially in patients with conduction delays (most commonly left bundle branch block – LBBB).
Function:
- Resynchronizes contraction of the left and right ventricles
- Improves:
- LV systolic function
- Cardiac output
- Symptoms and exercise tolerance
- Quality of life
- Reduces hospitalization and mortality
The New York Heart Association (NYHA) Classification
The NYHA classification is a functional system that categorizes HF based on the severity of symptoms and limitations to physical activity. It is widely used to assess baseline status, prognosis, and response to treatment.
| Class | Description | Example |
|---|---|---|
| Class I | No symptoms with ordinary physical activity | Can climb stairs, walk uphill, or do moderate activity without fatigue or dyspnea |
| Class II | Mild limitation of physical activity | Comfortable at rest, but ordinary activity (e.g., walking up 1 flight of stairs) causes fatigue, dyspnea, or palpitations |
| Class III | Marked limitation of physical activity | Comfortable at rest, but less than ordinary activity (e.g., dressing, walking across the room) causes symptoms |
| Class IV | Unable to carry out any physical activity without discomfort | Symptoms occur at rest (e.g., dyspnea, fatigue, palpitations). Any activity worsens discomfort |
Clinical Relevance:
- Used for staging, treatment planning, and eligibility for advanced therapies (e.g., ICDs, transplant)
- Often correlates with quality of life and hospitalization risk
- Can change over time depending on response to therapy
Consults #
- Cardiology: For advanced HF, device evaluation, or unclear etiology
- Electrophysiology: For ICD or CRT candidacy
- Nephrology: If renal dysfunction limits diuretic use or electrolyte control
- Palliative care: For refractory symptoms or advanced disease
Patient Education #
Counseling:
Daily Monitoring and Recognition of Decompensation
- Daily weight monitoring: Report if gain >2–3 lbs in 1 day or >5 lbs in a week
- Recognize early signs of decompensation: Increased dyspnea, edema, fatigue, orthopnea
Dietary and Lifestyle Modifications
- Low-sodium diet: <2 g/day
- Fluid restriction: <2 L/day if volume overloaded
- Maintain physical activity as tolerated: Encourage cardiac rehabilitation if eligible
- Smoking cessation: Essential for all patients
- Limit alcohol intake: Avoid excessive alcohol consumption
- Medication adherence: Take all medications as prescribed; do not stop beta-blockers or ACEi/ARNi abruptly
- Reassess EF after 3–6 months of optimal therapy
- Refer to cardiac rehab if stable
Screening:
- Depression or cognitive decline (common in chronic HF)
- Sleep apnea (especially in HFpEF or refractory HFrEF)
- Iron deficiency (common even without anemia; IV iron improves symptoms)
- Thyroid dysfunction (both hypo- and hyperthyroidism can worsen HF)
- Diabetes and lipid control (optimize comorbidity management)
- Arrhythmias, especially atrial fibrillation or bradyarrhythmias
- Frailty or sarcopenia, particularly in elderly HFpEF patients
Vaccinations:
Vaccination recommendations are based on CDC Advisory Committee on Immunization Practices (ACIP) guidelines, as USPSTF defers immunization recommendations to ACIP: [10]
Annual Vaccinations:
- Influenza vaccine: Annually for all HF patients [19]
Pneumococcal Vaccination (Updated 2024-2025):
- Adults aged ≥50 years who are PCV-naïve: One dose of PCV20, PCV21, or PCV15 (if PCV15 given, follow with PPSV23) [10,11]
- Adults aged ≥65 years: If previously received PCV13 but not PCV20/PCV21, complete series with PCV20 or PCV21[19,20]
COVID-19 Vaccination:
- Updated COVID-19 vaccine (2024-2025 formula): At least one dose for all adults, with additional doses for immunocompromised patients [19]
Tdap/Td:
- Tetanus-diphtheria-pertussis: If not up to date, ensure vaccination is current [19]
Note: The USPSTF does not make specific vaccination recommendations, deferring to the CDC’s Advisory Committee on Immunization Practices (ACIP) for immunization schedules.[19]
Follow-Up #
- Regular follow-up appointments should be scheduled to monitor disease progression and treatment response
- Frequency of follow-up depends on NYHA class and clinical stability (typically every 3-6 months for stable patients, more frequently for NYHA III-IV or recent decompensation)
- Each visit should include assessment of symptoms, functional status, medication adherence, weight trends, and vital signs
- Laboratory monitoring (renal function, electrolytes, BNP/NT-proBNP) should be performed as clinically indicated
- Repeat echocardiography should be considered after 3-6 months of optimal GDMT to reassess ventricular function
- Patients should be educated on when to seek urgent medical attention (rapid weight gain, worsening dyspnea, chest pain)
References #
1. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. https://doi.org/10.15585/mmwr.mm7401a1
2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
3. Bozkurt B, Ahmad T, Alexander K, et al. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics: An Updated 2024 Report from the Heart Failure Society of America. J Card Fail. 2024. https://doi.org/10.1016/j.cardfail.2024.07.001
4. Khan MS, Samman Tahhan A, Vaduganathan M, et al. Global epidemiology of heart failure. Nat Rev Cardiol. 2024;21:717-734. https://doi.org/10.1038/s41569-024-01046-6
5. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-3287. https://doi.org/10.1093/cvr/cvac013
6. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837-2849. https://doi.org/10.1161/CIRCULATIONAHA.104.500546
7. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. https://doi.org/10.1056/NEJMoa1005419
8. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-155. https://doi.org/10.1002/ejhf.1369
9. Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377(20):1964-1975. https://doi.org/10.1056/NEJMra1703100
10. Levy PD, Mebazaa A, Metra M, et al. Vasodilator Therapy in Acute Heart Failure: What We Know, That We Know So Little. Clin Pharmacol Ther. 2019;105(5):1067-1080. https://doi.org/10.1002/cpt.1363
11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200. https://doi.org/10.1093/eurheartj/ehw128
12. Cowie MR, Anker SD, Cleland JGF, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014;1(2):110-145. https://doi.org/10.1002/ehf2.12021
13. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2013;(5):CD005351. https://doi.org/10.1002/14651858.CD005351.pub3
14. Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-151. https://doi.org/10.1056/NEJMoa0707992
15. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-e327. https://doi.org/10.1161/CIR.0b013e31829e8776
16. Gorter TM, van Veldhuisen DJ, Bauersachs J, et al. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2016;13(10):610-623. https://doi.org/10.1038/nrcardio.2016.163
17. Maddox KEJ, Elkind MSV, Aparicio HJ, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation. 2024;149(25):e1288-e1304. https://doi.org/10.1161/CIR.0000000000001256
18. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485. https://doi.org/10.1056/NEJMoa2407107
19. Docherty KF, Henderson AD, Jhund PS, et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: A Prespecified Analysis of The FINEARTS-HF Trial. Circulation. 2024. https://doi.org/10.1161/CIRCULATIONAHA.124.072011
20. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule, United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(1):1-8. https://doi.org/10.15585/mmwr.mm7301a1
